4.7 Article

Establishment of a novel anaplastic large-cell lymphoma-cell line (COST) from a 'small-cell variant' of ALCL

Journal

LEUKEMIA
Volume 18, Issue 10, Pages 1693-1698

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/sj.leu.2403464

Keywords

ALK; tyrosine kinase receptor; anaplastic large-cell lymphoma; small-cell variant; translocation (2;5)

Ask authors/readers for more resources

Anaplastic large-cell lymphoma (ALCL) is a distinct biological and cytogenetic entity with a broad spectrum of morphological features ( common type, small-cell variant and lymphohistiocytic variant). Few cell lines of ALCL are available and they all originate from primary tumors demonstrating the common type morphology (ie large-sized lymphoma cells). We established a new ALCL cell line ( COST) from the peripheral blood of a patient with a small-cell variant of ALCL, at diagnosis. Cells growing in vitro and in SCID mice consisted of two populations, that is, small- and large-sized cells as seen in the patient's tumor. Both large and small malignant cells were positive for CD43/MT1 T-cell associated antigen, perforin, granzyme B and TIA-1, but negative for CD2, CD3, CD5, CD7, CD4 and CD8 antigens. Standard cytogenetic studies as well as multiplex FISH confirmed the presence of the canonical t(2; 5)(p23; q35) translocation, but also revealed additional numerical and structural abnormalities. The COST cell line is the first ALCL small- cell variant cell line, and thus provides a potentially useful tool for further functional and molecular studies that should improve our understanding of the small- cell variant of ALCL, which is more frequently complicated by a leukemic phase.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available